688428 InnoCare Pharma
- 11.66
- -0.04-0.34%
InnoCare Pharma News
Hong Kong stocks have experienced abnormal movement, with the concept of innovative drugs leading the way. The National Medical Products Administration has accelerated the approval of clinical pharmaceuticals, and many biotech companies have turned losses
Innovative drug concept has the highest increase. As of the time of writing, Akeso (01541) rose 60.42%, to HKD 6.16; Innocare (09926) rose 12.17%, to HKD 63.15; Innocare (09969) rose 6.19%, to HKD 5.83; Kanoa-B (02162) rose 5.56%, to HKD 39.85.
GTJA: Maintains a "shareholding" rating for CanSino Biologics. The first domestically produced IL-4R monoclonal antibody Kangyueda has been approved.
GTJA released a research report, maintaining a 'shareholding' rating for Connoah-B (02162), taking into account the early entry of CM310 into commercialization, and raising the revenue forecast for 2024 by 0.197 billion yuan (originally 0.156 billion yuan), maintaining the revenue forecast for 2025-2026 at 0.526/1.441 billion yuan. CM310 (known as Kangyueda) for the treatment of moderate to severe AD in adults was approved by the CDE for listing on September 12, becoming the first domestically approved IL-4R monoclonal antibody and the second globally approved, filling the gap in the domestic AD biologics field. The main viewpoints of GTJA are as follows:
Abnormal movement hits directly | Stocks of innovative drugs concept are on the rise, the 2024 ESMO conference is about to be held, and institutions suggest seizing the Q3 fundamentals turning point and industry catalysis.
Innovative drug concept stocks have risen, as of press time, Beigene (06160) rose 6.97%, to HKD 124.3; Innocare-B (02162) rose 4.92%, to HKD 37.35; Innocare (09969) rose 4.91%, to HKD 5.55.
Innocare (09969): Approximately 7.9394 million restricted shares will be listed for trading from September 23.
Innocare (09969) announced that approximately 7.9394 million restricted shares will be released on September 23, 2024...
InnoCare Pharma Agrees With US FDA For Phase 3 Clinical Trail of Orelabrutinib for PPMS Patients; Shanghai Shares Up 4%
HK Stocks Movement | Innocare (09969) surged more than 8% as the clinical research of Aprepitant in the USA Phase III was approved.
Innocare (09969) rose over 8% and as of the time of publication, it was up 8.32% at HKD 5.6, with a turnover of HKD 13.0947 million.
InnoCare Advances MS Treatment Into Phase 3 Trials
Hong Kong Stock Exchange Announcement: Innocare and FDA have reached an agreement to initiate Phase III study for the treatment of primary progressive multiple sclerosis (PPMS) patients with Obrutinib.
Innocare has reached an agreement with the FDA on the initiation of phase III study for the treatment of primary progressive multiple sclerosis (PPMS) patients with Ocrelizumab; jd.com logistics and Dada have entered into a freight service framework agreement.
InnoCare Pharma Ltd. (9969) Gets a Buy From Jefferies
Innocare (09969) has cancelled 1.65 million repurchased shares.
Innocare (09969) announced that on August 29, 2024, the company cancelled 1.65 million shares that had been repurchased...
InnoCare Pharma Limited (HKG:9969) Just Released Its Half-Year Results And Analysts Are Updating Their Estimates
InnoCare Pharma: Announcement of midterm performance for the six months ending on June 30, 2024.
Innocare Pharmaceutical Co., Ltd. Summary of 2024 Interim Report
Innocare Pharmaceuticals Co., Ltd. 2024 Half-year Report
Innocare (688428.SH) released its semi-annual performance, with a net loss of 0.262 billion yuan attributable to shareholders, narrowing year-on-year.
In the first half of 2024, innocare (688428.SH) released its report, achieving a revenue of 4...
InnoCare Pharma Announces Strong Mid-Year Growth
Innocare (09969.HK) announced its interim results with a 48.8% increase in sales revenue of Apatinib in the second quarter. Significant progress has been made in the rich pipeline of products under development.
On August 20, Ge Long Hui reported that the revenue of Innocare (09969.HK) for Apatinib increased by 30.0% from RMB 320.7 million in the same period last year to RMB 417.0 million in the six months ending June 30, 2024. Due to the rapid growth of MZL and effective sales execution, the sales revenue of Apatinib in the second quarter of 2024 increased by 48.8% compared with the second quarter of 2023. The total revenue increased by 11.2% from RMB 377.5 million in the same period last year to RMB 419.7 million in the six months ending June 30, 2024,
Express News | InnoCare Pharma - Total Hy Revenue Increased by 11.2% to RMB419.7 Mln
Express News | InnoCare Pharma - Hy Loss Decreased by 37.6% to RMB268.0 Million
Express News | InnoCare Pharma H1 Gross Profit RMB 359.6 Million
Analysis
Price Target
No Data
No Data